Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Non-Current Liabilities: 2021-2025

Historic Total Non-Current Liabilities for Foghorn Therapeutics (FHTX) over the last 2 years, with Sep 2025 value amounting to $294.0 million.

  • Foghorn Therapeutics' Total Non-Current Liabilities was N/A to $294.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $294.0 million, marking a year-over-year change of. This contributed to the annual value of $404.7 million for FY2022, which is 4.26% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Total Non-Current Liabilities stood at $294.0 million for Q3 2025, which was down 2.71% from $302.1 million recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Total Non-Current Liabilities high stood at $422.8 million for Q4 2021, and its period low was $104.9 million during Q3 2021.
  • Over the past 1 years, Foghorn Therapeutics' median Total Non-Current Liabilities value was $302.1 million (recorded in 2025), while the average stood at $305.2 million.
  • Data for Foghorn Therapeutics' Total Non-Current Liabilities shows a peak YoY increase of 290.36% (in 2022) and a maximum YoY decrease of 4.26% (in 2022) over the last 5 years.
  • Over the past 3 years, Foghorn Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $422.8 million in 2021, then decreased by 4.26% to $404.7 million in 2022, then reached $294.0 million in 2025.
  • Its last three reported values are $294.0 million in Q3 2025, $302.1 million for Q2 2025, and $319.5 million during Q1 2025.